The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Open accessAbstract
BACKGROUND: mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies. METHODS: -mutated cancer. Secondary end points included overall response and safety. RESULTS: -mutated cancer was greater with alpelisib-fulvestrant than with placebo-fulvestrant (26.6% vs. 12.8%); among patients with measurable disease in this cohort, the percentages were 35.7% and 16.2%, respectively. In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%). Diarrhea of grade 3 occurred in 6.7% of patients in the alpelisib-fulvestrant group, as compared with 0.3% of those in the placebo-fulvestrant group; no diarrhea of grade 4 was reported. The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively. CONCLUSIONS: -mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only 20 patients (6%) in SOLAR-1 had been previously exposed to a CDK4/6 inhibitor.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the use of which as a single-agent is now suboptimal in the second line”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperglycemia occurs early during therapy (median time of onset of about 2 weeks from initiation of alpelisib) with an incidence of $60% overall and typically resolves upon treatment cessation (220-222).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [220]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the PIK3CA-mutated cohort, alpelisib provided a PFS benefit of 11.0 months versus 5.7 months [hazard ratio (HR) for progression or death: 0.65; 95% confidence interval (CI) 0.50-0.85, P < 0.001].”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Toxicity was substantially increased in the alpelisib arm, especially hyperglycaemia, rash, gastrointestinal (GI) complaints (nausea, vomiting, loss of appetite, mucositis, diarrhoea) and fatigue, which lead to dose reductions/interruptions in around 70% of patients and discontinuations in 25%.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J. C. S., Bhattacharyya, G. S., Biganzoli, L., Cardoso, M. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,046
Self-citationUS Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,572
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Lopez, B. A., Barrios, C. H., Bergh, J. C. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,194
Self-citationO’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 657
Self-citationRugo, H. S., Rumble, R. B., Macrae, E. R., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L. J., Fowble, B. F., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 640
Self-citationConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationMiller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555
Baselga, J. M., Im, S., Iwata, H., Cortés, J., Laurentiis, M. D., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M. J., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 538
Self-citationFritsch, C. M., Huang, A., Chatenay‐Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D. A., Erdmann, D., Pover, A. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 504
Research works printed but not linked: 2
- Juric D, Janku F, Rodón J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol 2018 December 13 (Epub ahead of print).30543347
- Juric D Ciruelos E Rubovszky G et al. Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial. Presented at the San Antonio Breast Cancer Symposium San Antonio TX December 4–8 2018. abstract.
Cited by
Sorted by citations
Items 401–500 of 1,004
Sunami, K., Naito, Y., Aimono, E., Amano, T., Ennishi, D., Kage, H., Kanai, M., Komine, K., Koyama, T., Maeda, T., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01844-1 · Cited by 44
Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
Bertucci, A., Bertucci, F., & Gonçalvès, A. (2023) · Cancers · doi:10.3390/cancers15051416 · Cited by 45
Oliveira, M., Rugo, H. S., Howell, S. J., Dalenc, F., Cortés, J., Gómez, H., Hu, X., Toi, M., Jhaveri, K. L., Криворотько, П. В., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00373-5 · Cited by 50
Self-citationCannabinoids and Hormone Receptor-Positive Breast Cancer Treatment
Dobovišek, L., Krstanović, F., Borštnar, S., & Debeljak, N. (2020) · Cancers · doi:10.3390/cancers12030525 · Cited by 45
Prognostic and predictive parameters in breast pathology: a pathologist's primer
Allison, K. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-00704-7 · Cited by 46
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Gomatou, G., Trontzas, I. P., Ioannou, S., Drizou, M., Syrigos, N. K., & Kotteas, E. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06100-3 · Cited by 45
Zhang, Z., & Richmond, A. J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.648663 · Cited by 44
Jhaveri, K. L., Juric, D., Yap, Y. S., Cresta, S., Layman, R. M., Duhoux, F. P., Terret, C., Takahashi, S., Huober, J., Kundamal, N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1095 · Cited by 45
Self-citationBreast cancer management in 2021: A primer for the obstetrics and gynecology
Fleege, N. M. G., & Cobain, E. F. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2022.02.004 · Cited by 45
How I treat HER2-low advanced breast cancer
Schlam, I. M., Tolaney, S. M., & Tarantino, P. (2023) · The Breast · doi:10.1016/j.breast.2023.01.005 · Cited by 45
Rekha, T. N., & Shin, D. (2023) · Pharmaceuticals · doi:10.3390/ph16030339 · Cited by 45
Fankhauser, M., Bechmann, N., Lauseker, M., Goncalves, J., Favier, J., Klink, B., William, D., Gieldon, L., Maurer, J., Spöttl, G., et al. (2019) · Endocrinology · doi:10.1210/en.2019-00410 · Cited by 43
The current status of the clinical utility of liquid biopsies in cancer
Snow, A. E., Chen, D., & Lang, J. E. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1664290 · Cited by 44
Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020
Azim, H. A., Ghosn, M. G., Oualla, K., & Kassem, L. M. H. (2019) · The Breast Journal · doi:10.1111/tbj.13713 · Cited by 43
The emerging role of RNA N6-methyladenosine methylation in breast cancer
Zheng, F., Du, F., Zhao, J., Wang, X. L., Si, Y., Peng, J., Qian, H., Xu, B., & Yuan, P. (2021) · Biomarker Research · doi:10.1186/s40364-021-00295-8 · Cited by 42
Chamalidou, C., Fohlin, H., Albertsson, P., Arnesson, L.-G., Einbeigi, Z., Holmberg, E. C., Nordenskjöld, A. E., Nordenskjöld, B. A., Karlsson, P., & Linderholm, B. K. (2021) · The Breast · doi:10.1016/j.breast.2021.07.011 · Cited by 50
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
Grote, I., Bartels, S., Kandt, L. D., Bollmann, L., Christgen, H., Gronewold, M., Raap, M., Lehmann, U., Gluz, O., Nitz, U. A., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4376 · Cited by 43
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules
Goebel, G. L., Qiu, X., & Wu, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.006 · Cited by 44
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41
Next-Generation Endocrine Therapies for Breast Cancer
McDonnell, D. P., Wardell, S. E., Chang, C., & Norris, J. D. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03565 · Cited by 40
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Rugo, H. S., Raskina, K., Schrock, A. B., Madison, R. W., Graf, R. P., Sokol, E. S., Sivakumar, S., Lee, J., Fisher, V. A., Oxnard, G. R., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2115 · Cited by 42
Self-citationPI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
Sapon-Cousineau, V., Sapon-Cousineau, S., & Assouline, S. E. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00746-8 · Cited by 42
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling
Steelman, L. S., Chappell, W. H., Akula, S. M., Abrams, S. L., Cocco, L., Manzoli, L., Ratti, S., Martelli, A. M., Montalto, G., Cervello, M., et al. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100758 · Cited by 44
Nabieva, N., & Fasching, P. A. (2021) · Cancers · doi:10.3390/cancers13225643 · Cited by 45
A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer
Inglebert, M., Dettwiler, M., Hahn, K., Letko, A., Drögemüller, C., Doench, J. G., Brown, A., Memari, Y., Davies, H. R., Degasperi, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-21706-2 · Cited by 43
Loong, H. H.-F., Shimizu, T., Prawira, A., Tan, A. C., Tran, B., Day, D., Tan, D. S. P., Ting, F. I. L., Chiu, J. W. Y., Hui, M. N., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101586 · Cited by 46
Hempel, D., Ebner, F. K., Garg, A., Trepotec, Ž., Both, A., Stein, W., Gaumann, A. K. A., Güttler, L., Janni, W., deGregorio, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67393-9 · Cited by 42
Wang, D. G., M.S, D. M. B., Blinder, V. S., Bromberg, J., Drullinsky, P. R., Funt, S. A., Jhaveri, K. L., Lake, D. E., Lyons, T. G., Modi, S., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05726-y · Cited by 41
Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives
Sun, H., Dai, S., Xu, J., Liu, L., Yu, J., & Sun, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.848485 · Cited by 43
Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
Viganò, M., Milia, M. L., Grassini, M. V., Pugliese, N., Giorgio, M. D., & FAGIUOLI, S. (2023) · Cancers · doi:10.3390/cancers15061766 · Cited by 43
Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review
Panda, V. K., Mishra, B., Mahapatra, S., Swain, B., Malhotra, D., Saha, S., Khanra, S., Mishra, P., Majhi, S., Kumari, K., et al. (2025) · Cancers · doi:10.3390/cancers17020234 · Cited by 47
Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting
Qiang, M., Chen, Z., Liu, H., Dong, J., Gong, K., Zhang, X., Huo, P., Zhu, J., Shao, Y., Ma, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516583 · Cited by 45
Xi, J., & Ma, C. X. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00917-8 · Cited by 42
Tolaney, S. M., Im, Y., Calvo, E., Lu, Y., Hamilton, E. P., Forero, A., Bachelot, T., Maur, M., Fasolo, A., Tiedt, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0645 · Cited by 41
Self-citationJhaveri, K. L., Chang, M. T., Juric, D., Saura, C., Gambardella, V., Melnyk, A., Patel, M. R., Ribrag, V., Ma, C. X., Aljumaily, R. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2657 · Cited by 40
Self-citationKaminska, K. K., Akrap, N., Staaf, J., Alves, C. L., Ehinger, A., Ebbesson, A., Hedenfalk, I. A., Beumers, L., Veerla, S., Harbst, K., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01402-1 · Cited by 39
Turner, S. J., Chia, S., Kanakamedala, H., Hsu, W., Park, J., Chandiwana, D., Ridolfi, A., Yu, C., Zarate, J. P., & Rugo, H. S. (2021) · The Oncologist · doi:10.1002/onco.13804 · Cited by 41
Self-citationIntegrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer
Keup, C., Suryaprakash, V., Hauch, S., Storbeck, M., Hahn, P. F., Sprenger‐Haussels, M., Kolberg, H., Tewes, M., Hoffmann, O., Kimmig, R., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00902-1 · Cited by 40
Network approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
Krop, I. E., Jegede, O. A., Grilley-Olson, J. E., Lauring, J. D., Mitchell, E. P., Zwiebel, J. A., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L. V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00424 · Cited by 39
Senkus, E., Delaloge, S., Domchek, S. M., Conte, P., Im, S., Xu, B., Armstrong, A., Masuda, N., Fielding, A., Robson, M., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34525 · Cited by 39
Self-citationMittal, A., Moltó, C., Tamimi, F., Schlam, I. M., Sammons, S. L., Tolaney, S. M., & Tarantino, P. (2023) · Cancers · doi:10.3390/cancers15072015 · Cited by 41
“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”
Holler, A., Nguyen-Sträuli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s340741 · Cited by 47
Grizzi, G., Ghidini, M., Botticelli, A., Tomasello, G., Ghidini, A., Grossi, F., Fusco, N., Cabiddu, M., Savio, T., & Petrelli, F. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202965 · Cited by 40
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
Singh, A. P., Shum, E., Rajdev, L. N., Cheng, H., Goel, S., Perez-Soler, R., & Halmos, B. (2020) · Cancers · doi:10.3390/cancers12051156 · Cited by 40
Peterson, L. M., Kurland, B. F., Yan, F., Novakova-Jiresova, A., Gadi, V. K., Specht, J. M., Gralow, J. R., Schubert, E. K., Link, J. M., Krohn, K. A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244459 · Cited by 39
Kim, K., Kim, J., Sung, J. H., Suh, K. J., Lee, J. Y., Kim, S. H., Lee, J., Kim, J. W., Kim, Y. J., Kim, J. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68998-w · Cited by 40
Ogata, R., Kishino, E., Saitoh, W., Koike, Y., & Kurebayashi, J. (2020) · Breast Cancer · doi:10.1007/s12282-020-01150-8 · Cited by 39
Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification
Tsang, J. Y., & Tse, G. M.-K. (2021) · Modern Pathology · doi:10.1038/s41379-021-00736-7 · Cited by 39
Luo, R., Chong, W., Wei, Q., Zhang, Z., Wang, C., Ye, Z., Abu-Khalaf, M. M., Silver, D. P., Stapp, R., Jiang, W. I., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00278-w · Cited by 39
Combinatorial Power of cfDNA, CTCs and EVs in Oncology
Keup, C., Kimmig, R., & Kasimir‐Bauer, S. (2022) · Diagnostics · doi:10.3390/diagnostics12040870 · Cited by 40
Albanell, J., Pérez-García, J. M., Gil‐Gil, M., Curigliano, G., Ruíz-Borrego, M., Comerma, L., Gibert, J., Bellet, M., Bermejo, B., Calvo, L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1281 · Cited by 39
Targeting SHIP1 and SHIP2 in Cancer
Pedicone, C., Meyer, S. T., Chisholm, J. D., & Kerr, W. G. (2021) · Cancers · doi:10.3390/cancers13040890 · Cited by 42
Suppan, C., Graf, R., Jahn, S. W., Zhou, Q. X., Klocker, E. V., Bartsch, R., Terbuch, A., Kashofer, K., Regitnig, P., Lindenmann, J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01601-9 · Cited by 38
Sterba, M., Pokorná, P., Faberova, R., Pinková, B., Skotáková, J., Seehofnerová, A., Blatný, J., Janigova, L., Košková, O., Pálová, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-37468-4 · Cited by 38
Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma
Noch, E., Palma, L., Yim, I., Bullen, N., Qiu, Y., Ravichandran, H., Kim, J., Rendeiro, A. F., Davis, M. B., Elemento, O., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad117 · Cited by 38
Bansal, I., Pandey, A. K., & Ruwali, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1244597 · Cited by 41
Jhaveri, K. L., Accordino, M. K., Bedard, P. L., Cervantes, A. M. R., Gambardella, V., Hamilton, E. P., Italiano, A., Kalinsky, K. M., Krop, I. E., Oliveira, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00110 · Cited by 38
Self-citationMechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer
Zhang, J., Wang, Q., Wang, Q., Cao, J., Sun, J., & Zhu, Z. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03281-4 · Cited by 40
Genomic Characterization of de novo Metastatic Breast Cancer
Garrido-Castro, A. C., Spurr, L. F., Hughes, M. E., Li, Y. Y., Cherniack, A. D., Kumari, P., Lloyd, M. R., Bychkovsky, B., Barroso‐Sousa, R., Lascio, S. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1720 · Cited by 41
Pikman, Y., Tasian, S. K., Sulis, M. L., Stevenson, K. E., Blonquist, T. M., Winger, B. A., Cooper, T. M., Pauly, M. G., Maloney, K. W., Burke, M. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0564 · Cited by 38
Cai, Y., Xu, G., Wu, F. H., Michelini, F., Chan, C., Qu, X., Selenica, P., Ladewig, E., Castel, P., Cheng, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3232 · Cited by 38
Self-citationCiruelos, E., Rugo, H. S., Mayer, I. A., Lévy, C., Forget, F., Mingorance, J. I. D., Safra, T., Masuda, N., Park, Y. H., Juric, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01139 · Cited by 37
Self-citationChemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy.
Kaboli, P. J., İmani, S., Jomhori, M., & Ling, K. (2021) · Europe PMC (PubMed Central) · Cited by 38
Duffy, M. J., & Crown, J. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010099 · Cited by 40
Ha, M. J., Raghavendra, A. S., Kettner, N. M., Qiao, W., Damodaran, S., Layman, R. M., Hunt, K. K., Shen, Y., Tripathy, D., & Keyomarsi, K. (2022) · International Journal of Cancer · doi:10.1002/ijc.33959 · Cited by 38
Choi, B.-H., Rawat, V., Högström, J., Burns, P. A., Conger, K. O., Özgürses, M. E., Patel, J. M., Mehta, T. S., Warren, A., Selfors, L. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110278 · Cited by 38
Management of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia
Goncalves, M. D., & Farooki, A. (2022) · Integrative Cancer Therapies · doi:10.1177/15347354211073163 · Cited by 37
Genetic Testing Enhances the Precision Diagnosis and Treatment of Breast Cancer
Yang, T.-L., Li, W., Huang, T., & Zhou, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316607 · Cited by 45
Gu, H., Chen, C., Hou, Z.-S., He, X., Xie, S., Ni, J., Qian, C., Cheng, X., Jiang, T., Yang, C., et al. (2024) · Blood · doi:10.1182/blood.2023022202 · Cited by 39
Aredo, J. V., Jamali, A., Zhu, J., Heater, N. K., Wakelee, H. A., Vaklavas, C., Anagnostou, V., & Lu, J. M. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-481114 · Cited by 42
Lee, J. S., Yost, S. E., Blanchard, S., Schmolze, D. B., Yin, H. H., Pillai, R. K., Robinson, K., Tang, A., Martínez, N., Portnow, J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1202-4 · Cited by 37
Discovery through clinical sequencing in oncology
Donoghue, M. T. A., Schram, A. M., Hyman, D. M., & Taylor, B. S. (2020) · Nature Cancer · doi:10.1038/s43018-020-0100-0 · Cited by 38
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
Armaghani, A. J., & Han, H. S. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s219436 · Cited by 38
Tan, E. S., Cao, B., Kim, J., Al‐Toubah, T., Mehta, R. J., Centeno, B. A., & Kim, R. D. (2020) · Cancer · doi:10.1002/cncr.33364 · Cited by 37
Gallagher, E. J., Moore, H., Lacouture, M. E., Dent, S. F., Farooki, A., Goncalves, M. D., Isaacs, C., Johnston, A., Juric, D., Quandt, Z., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00613-x · Cited by 36
Self-citationKuno, I., Takayanagi, D., Asami, Y., Murakami, N., Matsuda, M., Shimada, Y., Hirose, S., Kato, M. K., Komatsu, M., Hamamoto, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98527-2 · Cited by 35
Novoplansky, O., Shnerb, A. B., Marripati, D., Jagadeeshan, S., Shareb, R. A., Conde‐López, C., Zorea, J., Prasad, M., Lulu, T. B., Yegodayev, K. M., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13500 · Cited by 37
Signaling pathways in colorectal cancer: implications for the target therapies
Song, Y., Chen, M., Wei, Y., Ma, X., & Shi, H. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00178-y · Cited by 42
Thomssen, C., Lüftner, D., Untch, M., Haidinger, R., Würstlein, R., Harbeck, N., Augustin, D., Briest, S., Ettl, J., Fasching, P. A., et al. (2020) · Breast Care · doi:10.1159/000505957 · Cited by 37
Small molecule targeting of SHIP1 and SHIP2
Kerr, W. G., Pedicone, C., Dormann, S., Pacherille, A., & Chisholm, J. D. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190775 · Cited by 38
Drullinsky, P. R., & Hurvitz, S. A. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05618-1 · Cited by 39
The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas
Lai, B. S. W., Tsang, J. Y., Poon, I. K., Shao, Y., Chan, S., Tam, F. K. Y., Cheung, S., Shea, K.-H., & Tse, G. M.-K. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0081 · Cited by 36
Genomic Signatures in Luminal Breast Cancer
Puppe, J., Seifert, T., Eichler, C., Pilch, H., Mallmann, P. K., & Malter, W. (2020) · Breast Care · doi:10.1159/000509846 · Cited by 37
Keup, C., Suryaprakash, V., Storbeck, M., Hoffmann, O., Kimmig, R., & Kasimir‐Bauer, S. (2021) · Cells · doi:10.3390/cells10020212 · Cited by 39
Basile, D., Gerratana, L., Corvaja, C., Pelizzari, G., Franceschin, G., Bertoli, E., Palmero, L., Zara, D., Alberti, M., Buriolla, S., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.02.015 · Cited by 37
Zañudo, J. G. T., Mao, P., Alcon, C., Kowalski, K. J., Johnson, G. N., Xu, G., Baselga, J. M., Scaltriti, M., Letai, A. G., Montero, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1208 · Cited by 37
PI3KCA Mutations in Uterine Cervix Carcinoma
Voutsadakis, I. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020220 · Cited by 35
Rodriguez, M. J., Perrone, M. C., Riggio, M., Palafox, M., Salinas, V., Elia, A. M., Salgueiro, N. D., Werbach, A., Marks, M. P., Kauffman, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29425-y · Cited by 36
Tong, Y., Fan, X., Liu, H., & Liang, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1495675 · Cited by 36
Microbiome metabolism of dietary phytochemicals controls the anticancer activity of PI3K inhibitors
Roichman, A., Zuo, Q., Hwang, S., Lu, W., Cordova, R. A., MacArthur, M. R., Boyer, J. A., Mitchell, S. J., Powers, J. R., Koval, S. A., et al. (2025) · Cell · doi:10.1016/j.cell.2025.04.041 · Cited by 38
Biologic therapy for advanced breast cancer: recent advances and future directions
Tarantino, P., Morganti, S., & Curigliano, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1752176 · Cited by 38
Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients
Tao, Z., Li, T., Feng, Z., Liu, C., Shao, Y., Zhu, M., Gong, C., Wang, B., Cao, J., Wang, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01023 · Cited by 36
Richard, F., Majjaj, S., Venet, D., Rothé, F., Pingitore, J., Boeckx, B., Marchiò, C., Clatot, F., Bertucci, F., Mariani, O., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2268 · Cited by 35
Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
Wilhoit, T., Patrick, J. M., & May, M. B. (2020) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2020.11.7.9 · Cited by 35
Galván-Morales, M. Á., Rodríguez, R. B., Cruz, J. R. S., & Teran, L. M. (2020) · Molecules · doi:10.3390/molecules25235686 · Cited by 37
Arend, R. C., Jackson-Fisher, A. J., Jacobs, I. A., Chou, J., & Monk, B. J. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1868937 · Cited by 35
Schettini, F., Giuliano, M., Giudici, F., Conte, B., Placido, P. D., Venturini, S., Rognoni, C., Leo, A. D., Locci, M., Jérusalem, G., et al. (2021) · Cancers · doi:10.3390/cancers13061458 · Cited by 34
Self-citationColombo, I., Genta, S., Martorana, F., Guidi, M., Frattini, M., Samartzis, E. P., Brandt, S., Gaggetta, S., Moser, L., Pascale, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1402 · Cited by 36
A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice
Boudreau, M. W., Duraki, D., WANG, L. C. H., Mao, C., Kim, J. E., Henn, M. A., Tang, B., Fanning, S. W., Kiefer, J., Tarasow, T. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1383 · Cited by 37
Metadata
- Authors
- André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., & Juric, D.
- Affiliations
- Université Paris-Sud (FR)
- From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l’Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) — all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt — both in Germany (S.L.); UCSF Helen Diller Family Comprehensive...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-16
- Volume
- 380
- Issue
- 20
- Pages
- 1929-1940
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945564879
- Cited by
- 2,622
- References
- 25
- Citations by year
- 2026: 314 · 2025: 356 · 2024: 370 · 2023: 329 · 2022: 375 · 2021: 450 · 2020: 345 · 2019: 81
- FWCI
- 231.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Hispana (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- alpelisib, PIK3CA mutation, hormone receptor-positive breast cancer, HER2-negative breast cancer, advanced breast cancer, PI3Kα inhibitor, fulvestrant, endocrine therapy, hyperglycemia, diarrhea, adverse events
- MeSH terms
- Fulvestrant, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diarrhea, Female, Humans, Middle Aged, Mutation, Receptors, Estrogen, Receptors, Progesterone, Thiazoles, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Hormonal, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
